Lokon Pharma

Next generation cancer immunotherapeutics

Our solution

Read more

Clinical trials


Phase I/II study for pancreatic cancer
Read more


Phase I/II study for patients with pancreatic-, biliary-, ovarian-, and colorectal cancer
Read more


Phase I/II study for patients with malignant melanoma
Read more


The LOAd family includes a range of novel oncolytic viruses with different immunostimulatory genes that are currently being evaluated for mechanisms-of-action (MOA) and proof-of-concept (POC).

See our pipeline

For patients

If you live in the US and have pancreatic cancer or melanoma, you may be eligible for inclusion in our clinical trials LOKON001 or LOKON003. If you live in Sweden and have pancreatic cancer, melanoma, or ovarian cancer, you may be eligible for inclusion in our clinical trials LOKON002 or LOKON003. If you are interested to participate as a study patient in our trials, please, discuss with your treating physician.

Read more

About Lokon

Lokon Pharma is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Read more

Press releases


September 28, 2022
Preliminary data from LOKON002, LOAd703 treatment of solid malignancies will be presented by Dr Emma Eriksson, Head of R&D at CICON.
June 5, 2022
Dr Benjamin Musher (Baylor College of Medicine) presented data from LOKON001 arm 1 study on pancreatic cancer at ASCO.
April 8, 2022
Lokon’s triple armed virus LOAd732 will be presented by Jessica Wenthe (Uppsala University) at AACR this year!


Malou efter 10
Bengt fick aggressiv cancer - hade ett år kvar att leva
Immunterapi på 100 sekunder
Malou efter 10
Forskarna om cancervaccinet: ”Behövs pengar”
Uppsala universitet
Immunterapi är ett nytt sätt att bekämpa cancer.